Omnicell, Inc.

OMCL • Medical - Equipment & Services

$34.37

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$1.59B

Growth

-1.7%

Cash Flow

5/5

Trend

Stable

Evidence

Positive free cash flow · 1.89Consistent free cash flow · 5/5Manageable debt level · 0.17Healthy liquidity · 1.43Expensive earnings multiple · 1014.72

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$34.37

Change0.00%

Shares Out46.13M

Market Cap$1.59B

Enterprise Value$1.48B

52W Range29.06 - 55.00

Beta0.97

P/E40.57

P/S1.27

P/B1.23

P/FCF11.67

EV/Sales1.19

Price$34.37

Change0.00%

Shares Out46.13M

Market Cap$1.59B

Enterprise Value$1.48B

52W Range29.06 - 55.00

Beta0.97

P/E40.57

P/S1.27

P/B1.23

P/FCF11.67

EV/Sales1.19

EV/EBITDA14.22

EV/FCF10.90

Earnings Yield2.47%

FCF Yield8.57%

Dividend Yield0.00%

Gross Margin42.88%

Oper. Margin0.98%

Profit Margin0.17%

Debt/Eq0.17

Current Ratio1.43

Quick Ratio1.22

Revenue 5Y-1.70%

Target$57.50

Target Upside67.30%

Target Median$57.50

Target Range50.00 - 65.00

Volume2.01M

Avg Volume662.64K

EPS Surprise0.22

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

27/100

Financial Strength

Debt, cash, stability

71/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

62/100

Why this score▼

Positive free cash flow · 1.89Consistent free cash flow · 5/5Manageable debt level · 0.17Healthy liquidity · 1.43Expensive earnings multiple · 1014.72Negative growth trend

Analyst view

Analyst sentiment and price target

OMCL

Analyst sentiment

Based on 19 analyst votes · 2026-09-05

74/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$50.00

Mean

$57.50

Median

$57.50

High

$65.00

Company Overview

IPO: 8/7/2001

Industry: Medical - Equipment & Services

P/B i: 1.23

Debt / Equity i: 0.17

Operating Margin: 0.98%

Net Margin: 0.17%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: 0.17

Current Ratio: 1.43

Quick Ratio: 1.22

Status: Good

Insider Transactions

Recent executive and insider activity

LIPPS RANDALL A

Transaction: 07/15/2026

SELL

Change

-10,000

Price

$47.00

Filing

07/17/2026

Type

SELL

Njoku Nnamdi

Transaction: 07/01/2026

BUY

Change

+12,309

Price

Not reported

Filing

07/06/2026

Type

BUY

Manley Corey J

Transaction: 05/18/2026

SELL

Change

-5,025

Price

$43.22

Filing

05/19/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
LIPPS RANDALL A	SELL	-10,000	$47.00	07/15/2026	07/17/2026
Njoku Nnamdi	BUY	+12,309	Not reported	07/01/2026	07/06/2026
Manley Corey J	SELL	-5,025	$43.22	05/18/2026	05/19/2026
Njoku Nnamdi	SELL	-3,090	$43.22	05/18/2026	05/19/2026
LIPPS RANDALL A	SELL	-12,347	$43.12	05/15/2026	05/19/2026
Manley Corey J	SELL	-4,041	$43.12	05/15/2026	05/19/2026
NUTT BRIAN H.	SELL	-226	$43.12	05/15/2026	05/19/2026
Njoku Nnamdi	SELL	-3,660	$43.12	05/15/2026	05/19/2026
NUTT BRIAN H.	BUY	+5,556	Not reported	04/01/2026	04/03/2026
Radford Harlan Baird	BUY	+37,037	Not reported	04/01/2026	04/03/2026
LIPPS RANDALL A	BUY	+90,939	Not reported	04/01/2026	04/03/2026
Manley Corey J	BUY	+25,132	Not reported	04/01/2026	04/03/2026
Njoku Nnamdi	BUY	+46,296	Not reported	04/01/2026	04/03/2026
Manley Corey J	SELL	-7,405	$34.69	03/16/2026	03/17/2026
Manley Corey J	SELL	-3,819	$34.40	03/15/2026	03/17/2026
Njoku Nnamdi	SELL	-8,456	$34.40	03/15/2026	03/17/2026
LIPPS RANDALL A	SELL	-15,642	$34.40	03/15/2026	03/17/2026
Manley Corey J	SELL	-4,243	$36.59	02/17/2026	02/18/2026
LIPPS RANDALL A	SELL	-5,294	$36.50	02/15/2026	02/18/2026
Manley Corey J	SELL	-2,022	$36.50	02/15/2026	02/18/2026

About the Company

Omnicell, Inc.

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Source - link

Peers

ASTH GDRX OMDA PGNY PHR SDGR SSII TDOC TXG UFPT

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.

PRNewsWire

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference.

Business Wire

Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research

Omnicell President Sells 6,753 Shares

The disposal comprised 6,753 shares representing a total transaction value of ~$250,000. The transaction reduced the insider's direct equity holdings by 4%.

The Motley Fool

Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL

Bank of America Corp DE raised its holdings in Omnicell, Inc. (NASDAQ: OMCL) by 31.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 580,875 shares of the company's stock after acquiring an additional 138,537 shares during the

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-28	0.33	0.55	0.22
2026-02-05	0.47	0.4	-0.07
2025-10-30	0.36	0.51	0.15
2025-07-31	0.31	0.45	0.14
2025-05-06	0.16	0.26	0.1
2025-02-06	0.57	0.6	0.03
2024-10-30	0.41	0.56	0.15
2024-08-01	0.16	0.51	0.35
2024-05-02	-0.08	0.03	0.11
2024-02-08	0.17	0.33	0.16
2023-11-02	0.45	0.62	0.17
2023-08-01	0.28	0.57	0.29